Medicare Competitive Bidding Makes Big Impression On U.S. Diabetes Device Earnings
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson and Abbott Laboratories each reported massive double-digit revenue drops for their U.S. diabetes product divisions in earnings reports this week, citing the impact of the national Medicare competitive bidding program for diabetes supplies. Roche had better-looking results for the most recent quarter, but also has taken a big hit from massive reimbursement cuts resulting from nationwide bidding.
You may also be interested in...
Medicare Durable Equipment Cuts Will Deepen In Next Round Of Competitive Bidding
Starting July 1, Medicare plans to pay 45 percent less than current fee-schedule rates for eight categories of DMEPOS in 91 cities, and 72 percent less nationwide for diabetes products.
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.
Device Week, March 8, 2019 – Scott Gottlieb Resigns
On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?